Patent ID: 8729043
Filing Date: 2014-05-20
Classification: A61K,A61P,C07K,C12N

Abstract:
1. A method of treating a tumor or tumor metastases that express MET comprising administering to a patient in need thereof a lentiviral vector containing a nucleotide sequence encoding i) the anti-Met monoclonal antibody AntiMET-R, ii) a fragment containing the epitope binding region of the anti-Met monoclonal antibody AntiMET-R, or iii) a genetically engineered or humanized antibody containing the complementarity determining regions (CDRs) of the anti-Met monoclonal antibody AntiMET-R, wherein CDR-H1 is SEQ ID NO.:8, CDR-H2 is SEQ ID NO.:9, CDR-H3 is SEQ ID NO.:10, CDR-L1 is SEQ ID NO.:11, CDR-L2 is SEQ ID NO.:12 and CDR-L3 is SEQ ID NO.:13 in an amount sufficient to effect said treatment, wherein said nucleotide sequence is expressed so as to cause shedding of the extracellular portion of HGFR and HGFR down regulation in said tumor or tumor metastasis cells and thereby inducing an anti-tumor or anti-metastatic effect, wherein said vector is administered in form of a particle by intra-tumor infusion and wherein said anti-Met monoclonal antibody AntiMET-R is produced by the hybridoma cell line ICLC PD 05006.